Operative considerations in resection of hilar cholangiocarcinoma  by Parikh, Alexander A. et al.
Operative considerations in resection of hilar cholangiocarcinoma
ALEXANDER A. PARIKH1, EDDIE K. ABDALLA2 & JEAN-NICOLAS VAUTHEY2
1Vanderbilt University Medical Center, Division of Surgical Oncology, Nashville, TN and 2University of Texas
M.D. Anderson Cancer Center, Department of Surgical Oncology, Houston, TX, USA
Abstract
This article reviews the preoperative evaluation and operative considerations in patients with hilar cholangiocarcinoma. The
preoperative evaluation is based on the imaging evaluation of the longitudinal and radial extent of the tumour along and
around the hepatic duct confluence. The use of portal vein embolization to increase the safety of extended hepatectomy and
the extent of surgical resection (caudate lobe and portal vein) are discussed within the context of recently published series.
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Introduction
Of the estimated 6950 cases of extrahepatic biliary
tract cancer that occur each year in the United States,
approximately one-half are proximal bile duct adeno-
carcinoma (hilar cholangiocarcinoma—CCA) [1,2].
These tumours develop in a confined space between
the portal vein, hepatic artery, liver and pancreas and
present unique pathological and anatomical features
[2]. Left untreated, patients rarely survive more than 6
months and resection remains the only hope for long-
term survival.
The purposes of surgical resection are twofold—to
relieve the biliary obstruction caused by the tumour
and to provide hope of cure for some patients.
Although resection generally affords the patient the
best chance for survival, only a small subset of patients
with hilar CCA are candidates for surgical resection. In
addition, resection of hilar CCA is often associated
with significant morbidity and therefore proper patient
selection is paramount. For those patients deemed
unresectable, palliative options may be entertained.
In spite of recent advances in the evaluation and
treatment of hilar CCA, several controversies remain.
These include the role of preoperative portal vein
embolization (PVE), the type and extent of resection,
resection of the caudate lobe or portal vein and the
value of lymphadenectomy. These topics will be the
subject of this review.
Criteria of unresectability
The ultimate goal of surgical resection is to achieve
negative margins, i.e. R0 resection. In contrast to most
gastrointestinal cancers, in which clear margins are
common, resection for hilar CCA only allows for
limited surgical clearance margins [3]. This may
explain why even curative resections are associated
with high local recurrence rates [4]. These limitations
and the associated perioperative risks emphasize the
need for detailed preoperative evaluation.
In general, criteria of unresectability include [2]:
(1) bilateral intrahepatic bile duct spread to secondary
or segmental biliary radicals; (2) involvement of the
main trunk of the portal vein (except in unusual
circumstances); (3) bilobar involvement of hepatic
arterial and/or portal venous branches; (4) a combina-
tion of unilateral hepatic arterial involvement with
cholangiographic evidence of extensive contralateral
duct spread.
Classification of hilar cholangiocarcinoma/
extent of resection
In order to determine resectability the preoperative
evaluation should provide information regarding:
(1) ductal involvement and (2) the radial extent of
the tumour (involvement of the vasculature and the
extent of hypertrophy/atrophy). Typically, this is
achieved by: (1) direct cholangiography (percutaneous
or endoscopic retrograde) or magnetic resonance
cholangiography and (2) multiphasic intravenous
contrast-enhanced helical computed tomography
(CT) with thin cuts in an oblique coronal plane. This
CT is also used to obtain a three-dimensional
volumetric reconstruction of the future liver remnant
to determine the need for portal vein embolization.
Correspondence: Jean-Nicolas Vauthey, MD, Department of Surgical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe
Boulevard, Unit 444, Houston, TX 77030, USA. Tel:+1 713 792 2022. Fax:+1 713 792 0722. E-mail: jvauthey@mdanderson.org
HPB, 2005; 7: 254–258
ISSN 1365-182X print/ISSN 1477-2574 online # 2005 Taylor & Francis
DOI: 10.1080/13651820500373093
In most resectable cases, the resection strategy will
depend on the longitudinal tumour extent as defined
based on the cholangiographic classification of Bis-
muth and Corlette [5] (Figure 1).
Local or hilar resections of the extrahepatic biliary
tract represent the least extensive resection and in our
opinion should only be performed—if at all—in mid
bile duct CCA. Although no prospective randomized
trials comparing common bile duct versus combined
hepatic and common bile duct resection for hilar CCA
have been done, several retrospective studies have
indicated improved negative margin rates and
increased overall survival with combined resections,
despite higher overall morbidity and mortality [6–12].
Recent studies have also shown that the complication
rates with major hepatic resections have declined
[7,9,11,13]. The extent of resection and the survival
data from series of patients who underwent resection of
proximal CCA are presented in Table I [9,11,14–17].
Ductal anatomy
A thorough knowledge of hepatic ductal anatomy and
its variants is essential in the planning of surgical
resection. The right hepatic duct is inconstant and
short (51 cm). In contrast, the left hepatic duct is
present in 97% of patients and is longer (1–5 cm)
[15,18,19]. In order to achieve negative margins for
type I, II and IIIa tumours, therefore, we recommend
an extended right hepatectomy with resection of
segment IV (Figure 2). The relatively long and extra-
hepatic course of the left hepatic duct can thus be
utilized for reconstruction while optimizing surgical
clearance margins. In contrast, for type IIIb hilar
tumours, we recommend a left or extended left
hepatectomy with resection of segment IV (Figure 2).
Caudate lobe resection
Removal of the caudate lobe during hepatic resection
for CCA, although somewhat controversial, has also
gained acceptance. Proponents argue that improved
margins can be achieved with minimal additional
morbidity, while others suggest that removal should
be performed in selected cases. Although specific
studies comparing routine and selective caudate
resection have not been performed, several studies
have reported caudate lobe involvement in a high
percentage of resected specimens, and the caudate lobe
is the most frequent site of hepatic recurrence
[12,20,21].
Removal of the caudate lobe requires a thorough
understanding of its anatomy and relationship to the
hepatic vasculature and ductal system. The caudate
lobe (segment I) is divided into three subsegments
(Figure 3). To the right of the inferior vena cava (IVC)
and portal structures lies the caudate process while to
the left of these structures and frequently visible
beneath the lesser omentum lies Spiegel’s lobe or the
papillary process of the caudate lobe. The paracaval
portion of the caudate lobe lies between these two and
drapes the IVC [22].
We recommend that resection of the caudate
process and paracaval caudate lobe be performed in
all hepatic resections for hilar CCA since these lie
in close proximity to the hepatic duct confluence.
In performing a left hepatectomy for Bismuth–Corlette
type IIIb tumours, Spiegel’s lobe (papillary process)
should also be removed. Whether or not Spiegel’s lobe
(papillary process) needs to be removed routinely or on
the basis of tumour extent in type I-IIIa hilar CCA will
need to be determined by further studies.
Portal vein resection
Portal vein resection and reconstruction has been
traditionally performed only if gross invasion was
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Figure 1. Bismuth–Corlette classification of potentially resectable
(excludes type IV) hilar cholangiocarcinoma.
Table I. Results for resection of hilar cholangiocarcinoma
Reference
Patients
resected (n)
Hepatic
resection (%)
Curative (R0)
resection (%)
Operative
mortality (%)
5-year survival after
R0 resection (%)
Launois et al. 1999 [14] 40 62 80 12 –
Kosuge et al. 1999 [9] 65 88 52 9 52
Miyazaki et al. 1999 [11] 93 86 70 10 38
Neuhaus et al. 1999 [15] 95 84 46 6 37
Nimura et al. 2000 [16] 142 90 76 – –
Jarnagin et al. 2001 [17] 80 78 78 10 30
Operative considerations in resection of hilar cholangiocarcinoma 255
noted at the time of hepatic resection or in select cases
with invasion detected on preoperative imaging
[12,23]. More recently, portal vein resection has been
proposed as part of a “no-touch” technique in resection
of hilar CCA. In this study, portal vein resection
was utilized in both right and left hepatectomies
and histologically confirmed tumour infiltration was
detected in 22% of specimens (50% in left-sided
resections). Although portal vein resection was
associated with improved survival, this was only
evident when initial 60-day deaths were excluded.
Overall 60-day mortality after resection was 17%,
however, as compared with 5% for patients without
portal vein resection [15]. Considering this high
complication rate and the lack of portal vein infiltration
in the majority of specimens, routine resection of the
portal vein cannot be recommended without additional
evidence.
Preoperative portal vein embolization
A concern regarding major liver resection for hilar
CCA is the potential for postoperative hepatic insuffi-
ciency reported in up to 32% of patients after
combined resections [24]. Although survival after
480% hepatic resection is possible in adults, extensive
resections are associated with an increased risk of
complications and postoperative hepatic dysfunction
[25,26]. An innovative strategy to increase the
volume and function of the future remnant liver is
the use of preoperative portal vein embolization
(PVE) [27]. With this procedure portal flow and the
hepatrophic factors (interleukin-6, insulin, glucagon)
are redistributed, resulting in ipsilateral apoptosis and
contralateral regeneration.
Several studies have reported that preoperative PVE
is safe and results in atrophy of the embolized lobe and
hypertrophy of the remnant liver [28–31]. Although
preoperative PVE has not been compared to resection
alone in a prospective randomized trial, there are
significant data that support the safety and efficacy of
this technique [23,32–34]. For hilar CCA, therefore,
if extensive hepatic resection is required, preoperative
PVE should be strongly considered in patients with an
anticipated future liver remnant volume of 420% of
the total estimated liver volume [34,35].
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Figure 2. Extent of hepatic resection for types I-IIIb hilar cholangiocarcinoma.
Figure 3. Anatomy of the caudate lobe (segment I). Reproduced
with permission from: Abdalla EK, Vauthey JN, Couinaud C. The
caudate lobe of the liver: implications of embryology and anatomy for
surgery. Surg Oncol Clin North Am. 2002;11(4):835–48.
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Lymph node metastasis
Nodal status, including regional and para-aortic nodes,
has been shown to be an important predictor of survival
after resection for hilar CCA [9,36,37]. Some authors
have reported a benefit of lymphadenectomy with
hepatic resection for CCA, although routine regional
and para-aortic lymphatic resection have been
performed in 3–53%, making comparisons difficult
[9,11,12,15,36]. A recent study from Japan reported
on 110 patients with 2652 resected lymph nodes, with
14% containing metastatic disease [38]. Although
lymph node resection was reported as safe, that study
and several others have shown that only 1–5% of
patients with positive lymph nodes, particularly when
outside the regional area, will survive 5 years
[9,11,15,36–39]. These data suggest that lymph node
dissection may add valuable staging and prognostic
information, but that the impact on overall survival is
minimal. In light of this, routine lymphadenectomy
beyond the hepatoduodenal ligament cannot be
recommended.
Summary
The surgical treatment of hilar CCA requires detailed
preoperative evaluation to define the perioperative
strategy. Although a margin-negative resection offers a
chance for long-term survival for some, most patients
are unresectable at diagnosis. When considering
resection for CCA, formal hepatic resection is recom-
mended for type I-III hilar CCAs. Resection of the
caudate lobe is now generally recommended, although
current data do not support routine resection of
Spiegel’s lobe except with type IIIb tumours. Portal
vein resection is associated with increased compli-
cations and mortality and routine resection is not
recommended. Similarly, routine resection of lymph
nodes outside of the regional area does not lead to
improved survival. Finally, in patients with potentially
inadequate future liver remnant volume, preoperative
PVE should be considered to minimize postoperative
hepatic dysfunction and to optimize outcome.
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